Yong-Jin Kim (YongJin Kim)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 7

Top Venues

Current medical research and opinion

Future oncology (London, England)

PharmacoEconomics

Journal of comparative effectiveness research

University of Waterloo (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

University of Waterloo Sep 01 2017

Canada

PHD :: School of Public Health and Health Systems

Publications

Yuichi Yoshida, Keiichi Tozawa, Ryo Koto, Chikako Iwao, Yong-Jin Kim, Lu Ban, Volkan Barut
Patient characteristics, treatment patterns, healthcare resource utilization, and costs among patients diagnosed with neurofibromatosis type 1 with and without plexiform neurofibromas in Japan. Current medical research and opinion 40 (4) (2024)
Yuichi Yoshida, Keiichi Tozawa, Ryo Koto, Chikako Iwao, Yong-Jin Kim, Lu Ban, Volkan Barut
Patient characteristics, treatment patterns, healthcare resource utilization, and costs among patients diagnosed with neurofibromatosis type 1 with and without plexiform neurofibromas in Japan. Current medical research and opinion 40 (4) (2024)
Yuichi Yoshida, Keiichi Tozawa, Ryo Koto, Chikako Iwao, Yong-Jin Kim, Lu Ban, Volkan Barut
Patient characteristics, treatment patterns, healthcare resource utilization, and costs among patients diagnosed with neurofibromatosis type 1 with and without plexiform neurofibromas in Japan. Current medical research and opinion 40 (4) (2024)
Yuichi Yoshida, Keiichi Tozawa, Ryo Koto, Chikako Iwao, Yong-Jin Kim, Lu Ban, Volkan Barut
Patient characteristics, treatment patterns, healthcare resource utilization, and costs among patients diagnosed with neurofibromatosis type 1 with and without plexiform neurofibromas in Japan. Current medical research and opinion (2024)
Yong-Jin Kim, Mark Oremus, Helen H Chen, Thomas McFarlane, Danielle Fearon, Susan Horton
Factors affecting treatment selection and overall survival for first-line EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Journal of comparative effectiveness research 10 (3) (2021)
Yong-Jin Kim, Mark Oremus, Helen H Chen, Thomas McFarlane, Danielle Fearon, Susan Horton
Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada. PharmacoEconomics 39 (5) (2021)
Yong-Jin Kim, Mark Oremus, Helen H Chen, Thomas McFarlane, Devanshi Shah, Susan Horton
Real-world effectiveness of nivolumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Future oncology (London, England) 16 (27) (2020)

Yong-Jin Kim.css-eqlu8i{font-size:small;padding-left:4px;} (YongJin Kim)

Publication Activity (10 Years)

Top Topics

Top Venues

Yong-Jin Kim (YongJin Kim)